DYNPORT VACCINE COMPANY LLC
Federal contract awards won by DYNPORT VACCINE COMPANY LLC (UEI LXNEGTYDR755), 1997–2025 — public record from USAspending.
Showing awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
13
awards
$863,752,669
total value
2
agencies
Agencies buying from DYNPORT VACCINE COMPANY LLC
What DYNPORT VACCINE COMPANY LLC sells
541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) (5)541711 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (4)541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) (2)541712 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) (1)
Awards
"EVALUATION AND TESTING SERVICES (ETS) FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASES.
Department of Health and Human Services · $136,588,701 · Sep 30, 2025
PRECLINICAL SERVICES FOR BIOPHARMACEUTICAL PRODUCT DEVELOPMENT: IDIQ PARENT CONTRACT
Department of Health and Human Services · $30,000,000 · Sep 8, 2023
DIAGNOSTIC PRE-CLINICAL SERVICES PROGRAM -IDIQ - DYNPORT
Department of Health and Human Services · $36,000,000 · Jun 20, 2023
EPCTU
Department of Health and Human Services · $1,800,783 · May 15, 2023
EVALUATION OF CELL LINES PRODUCING A MONOCLONAL ANTIBODY, AND PRODUCTION AND CHARACTERIZATION OF A CGMP MASTER CELL BANK
Department of Health and Human Services · $1,213,178 · Jul 20, 2022
TASK ORDER 75N93022F00001 BASE AWARD
Department of Health and Human Services · $381,725 · Jan 21, 2022
EARLY PHASE CLINICAL TRIAL UNITS (EPCTU)
Department of Health and Human Services · $346,610,277 · Jan 14, 2022
PHASE I TASK AREA B -21-0013 - BASE
Department of Health and Human Services · $3,292,190 · Dec 14, 2021
STABILITY TESTING
Department of Defense · $8,345,012 · Aug 6, 2021
PHASE 1
Department of Health and Human Services · $3,804,631 · May 13, 2021
IGF::OT::IGF - RESEARCH&DEVELOPMENT IN SUPPORT OF THE US ARMY MEDICAL MATERIEL DEVELOPMENT ACTIVITY (USAMMDA) FOR THE PERFORMANCE OF A PHASE I, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE LONG-TERM OPHTHALMIC SAFETY OF TAFENOQUINE VERSUS PLACEBO.
Department of Defense · $24,654,606 · Mar 22, 2017
PROGRAM REPORTING - TECHNICAL
Department of Defense · $257,417,661 · May 9, 2013
Researching this competitor? BidCatch doesn't just show you what they won — it sends you the open bids in your trade every morning, before they're awarded. Free for 14 days, then $49.99/month.
Search open bids